Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection

Jimin Xu, Judith Berastegui-Cabrera, Haiying Chen, Jerónimo Pachón, Jia Zhou, Javier Sánchez-Céspedes

Research output: Contribution to journalArticle

1 Scopus citations


The effective treatment of adenovirus (HAdV) infections in immunocompromised patients still poses great challenges. Herein, we reported our continued efforts to optimize a series of salicylamide derivatives as potent inhibitors of HAdV infection. Of these, nine compounds (11, 13, 14, 17, 20, 58, 60, 62, and 70) showed significantly improved anti-HAdV activities with nanomolar to submicromolar IC50 values and high selectivity indexes (SI > 100), indicating better safety windows, compared to those of the lead compound niclosamide. Our mechanistic assays suggest that compounds 13, 62, and 70 exert their activities in the HAdV entry pathway, while compounds 14 and 60 likely target the HAdV DNA replication, and 11, 17, 20, and 58 inhibit later steps after DNA replication. Given the broad anti-viral activity profile of niclosamide, these derivatives may also offer therapeutic potential for other viral infections.

Original languageEnglish (US)
Pages (from-to)3142-3160
Number of pages19
JournalJournal of Medicinal Chemistry
Issue number6
StatePublished - Mar 26 2020


ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this